Jazz, Hikma, class plaintiffs get final settlement nod in US Xyrem antitrust case
MLex Summary: Jazz Pharmaceuticals, Hikma Pharmaceuticals and a class of indirect purchaser plaintiffs got final settlement approval from a California federal judge for overlapping claims alleging the defendants engaged in a...To view the full article, register now.
Already a subscriber? Click here to view full article